Mirum Pharmaceuticals Deal History & Licensing Activity
Mirum Pharmaceuticals is a biotech headquartered in USA. Over the past three years, Mirum Pharmaceuticals has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 14 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
3
Active Trials
14
Top Modality
Other
Focus Area
Infectious Disease
Mirum Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Mirum Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Bluejay viral/liver disease assets | Bluejay Therapeutics | Other | Unknown | acquisition | May 24, 2026 |
| phase 3 hepatitis B/D drug | Bluejay Therapeutics | Small Molecules | Phase 3 | acquisition | Mar 17, 2026 |
Mirum Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Mirum Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Mirum Pharmaceuticals Strategic Signals
Key indicators of Mirum Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Mirum Pharmaceuticals Clinical Pipeline
Mirum Pharmaceuticals has 14 active clinical trials across 4 development phases.
4
Unknown
1
Phase 4
6
Phase 2
3
Phase 3
See How Your Asset Matches Mirum Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Mirum Pharmaceuticals Licensing & Deal Activity
Mirum Pharmaceuticals is a biotech company based in USA that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Mirum Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Mirum Pharmaceuticals include Infectious Disease (4 deals and trials), Infectious (4 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Mirum Pharmaceuticals has shown particular interest in other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Mirum Pharmaceuticals and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Mirum Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.